Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Peptic Ulcer

  Free Subscription

Articles published in Helicobacter

Retrieve available abstracts of 195 articles:
HTML format

Single Articles

    June 2022
  1. MA J, Yu M, Shao QQ, Yu XC, et al
    Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
    Helicobacter. 2022 Jun 15:e12911. doi: 10.1111/hel.12911.
    PubMed     Abstract available

  2. SOUISSI S, Makni C, Belhadj Ammar L, Bousnina O, et al
    Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis: Results of a prospective study.
    Helicobacter. 2022 Jun 13:e12910. doi: 10.1111/hel.12910.
    PubMed     Abstract available

  3. XIAO W, Ma ZS
    Influences of Helicobacter pylori infection on diversity, heterogeneity, and composition of human gastric microbiomes across stages of gastric cancer development.
    Helicobacter. 2022 Jun 9:e12899. doi: 10.1111/hel.12899.
    PubMed     Abstract available

    May 2022
  4. INOKUCHI K, Mori H, Matsuzaki J, Hirata K, et al
    Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
    Helicobacter. 2022 May 29:e12900. doi: 10.1111/hel.12900.
    PubMed     Abstract available

  5. AKAR M, Saticioglu IB, Karakaya E, Kayman T, et al
    Two novel sequence types of Helicobacter pylori strains: The first report from Turkey.
    Helicobacter. 2022 May 23:e12907. doi: 10.1111/hel.12907.

  6. HE C, Peng C, Xu X, Li N, et al
    Probiotics mitigate Helicobacter pylori-induced gastric inflammation and premalignant lesions in INS-GAS mice with the modulation of gastrointestinal microbiota.
    Helicobacter. 2022 May 9:e12898. doi: 10.1111/hel.12898.
    PubMed     Abstract available

  7. PHUNG HTT, Deenonpoe R, Suttiprapa S, Mairiang E, et al
    Persistent advanced periductal fibrosis is associated with cagA-positive Helicobacter pylori infection in post-praziquantel treatment of opisthorchiasis.
    Helicobacter. 2022 May 9:e12897. doi: 10.1111/hel.12897.
    PubMed     Abstract available

    April 2022
  8. SAIF N, Jensen N, Farrar E, Blackstone S, et al
    Prevalence of Helicobacter pylori infection among resettled refugees presenting to a family medicine clinic in the United States.
    Helicobacter. 2022 Apr 28:e12894. doi: 10.1111/hel.12894.
    PubMed     Abstract available

  9. HU Y, Xu X, Ouyang YB, He C, et al
    Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.
    Helicobacter. 2022 Apr 25:e12896. doi: 10.1111/hel.12896.
    PubMed     Abstract available

  10. LI C, Lu C, Gong L, Liu J, et al
    SHP2/SPI1axis promotes glycolysis and the inflammatory response of macrophages in Helicobacter pylori-induced pediatric gastritis.
    Helicobacter. 2022 Apr 19:e12895. doi: 10.1111/hel.12895.
    PubMed     Abstract available

  11. JIANG F, Guo CG, Cheung KS, Li B, et al
    Age of eradication and failure rates of clarithromycin-containing triple therapy for Helicobacter pylori: A 15-year population-based study.
    Helicobacter. 2022 Apr 12:e12893. doi: 10.1111/hel.12893.
    PubMed     Abstract available

  12. CHUA BQY, Chong VWS, Teng TZJ, Chia CTW, et al
    Does technology-enhanced communication improve Helicobacter pylori eradication outcomes?-A meta-analysis.
    Helicobacter. 2022 Apr 1:e12890. doi: 10.1111/hel.12890.
    PubMed     Abstract available

  13. SONG Z, Chen Y, Lu H, Zeng Z, et al
    Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study.
    Helicobacter. 2022 Apr 1:e12889. doi: 10.1111/hel.12889.
    PubMed     Abstract available

    March 2022
  14. KOWADA A, Asaka M
    Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.
    Helicobacter. 2022 Mar 27:e12886. doi: 10.1111/hel.12886.
    PubMed     Abstract available

  15. HSIEH H, Yang HB, Sheu BS, Yang YJ, et al
    Atrophic gastritis in Helicobacter pylori-infected children.
    Helicobacter. 2022 Mar 20:e12885. doi: 10.1111/hel.12885.
    PubMed     Abstract available

  16. POLIVANOVA TV, Malaty H, Vshivkov VA
    Epidemiology Helicobacter pylori infection in children in the Tyva Republic (Russia).
    Helicobacter. 2022 Mar 13:e12882. doi: 10.1111/hel.12882.
    PubMed     Abstract available

  17. KOUNTOURAS J, Kazakos E, Polyzos SA, Chatzopoulos D, et al
    GM-CSF as a potential candidate of a vaccine-induced reduction of Helicobacter pylori infection.
    Helicobacter. 2022 Mar 7:e12884. doi: 10.1111/hel.12884.

  18. YOKOTA K, Osaki T, Hayashi S, Yokota SI, et al
    Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing.
    Helicobacter. 2022 Mar 7:e12874. doi: 10.1111/hel.12874.
    PubMed     Abstract available

  19. MORAIS S, Costa A, Albuquerque G, Araujo N, et al
    "True" Helicobacter pylori infection and non-cardia gastric cancer: A pooled analysis within the Stomach Cancer Pooling (StoP) Project.
    Helicobacter. 2022 Mar 2:e12883. doi: 10.1111/hel.12883.
    PubMed     Abstract available

    February 2022
  20. EL HAFA F, Wang T, Ndifor VM, Jin G, et al
    Association between Helicobacter pylori antibodies determined by multiplex serology and gastric cancer risk: A meta-analysis.
    Helicobacter. 2022 Feb 24:e12881. doi: 10.1111/hel.12881.
    PubMed     Abstract available

  21. ZHOU BG, Yan XL, Wan LY, Zhang Q, et al
    Effect of enhanced patient instructions on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials.
    Helicobacter. 2022 Feb 18:e12869. doi: 10.1111/hel.12869.
    PubMed     Abstract available

  22. LI H, Shen Y, Song X, Tang X, et al
    Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing.
    Helicobacter. 2022 Feb 12:e12873. doi: 10.1111/hel.12873.
    PubMed     Abstract available

  23. ZHA J, Li YY, Qu JY, Yang XX, et al
    Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis.
    Helicobacter. 2022 Feb 12:e12880. doi: 10.1111/hel.12880.
    PubMed     Abstract available

  24. SHAO QQ, Yu XC, Yu M, Ma J, et al
    Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Helicobacter. 2022 Feb 12:e12876. doi: 10.1111/hel.12876.
    PubMed     Abstract available

  25. LI Y, Huang Z, Shang Y, Xie X, et al
    Exploration of the molecular mechanisms underlying the antibiotic resistance of Helicobacter pylori: A whole-genome sequencing-based study in Southern China.
    Helicobacter. 2022 Feb 6:e12879. doi: 10.1111/hel.12879.
    PubMed     Abstract available

  26. SHI Y, Zheng H, Wang M, Ding S, et al
    Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
    Helicobacter. 2022 Feb 3:e12878. doi: 10.1111/hel.12878.
    PubMed     Abstract available

    January 2022
  27. QIANG L, Hu J, Tian M, Li Y, et al
    Extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles in atherosclerosis.
    Helicobacter. 2022 Jan 31:e12877. doi: 10.1111/hel.12877.
    PubMed     Abstract available

  28. VAILLANT L, Oster P, McMillan B, Orozco Fernandez E, et al
    GM-CSF is key in the efficacy of vaccine-induced reduction of Helicobacter pylori infection.
    Helicobacter. 2022 Jan 29:e12875. doi: 10.1111/hel.12875.
    PubMed     Abstract available

  29. DI MARIO F, Crafa P, Barchi A, Franzoni L, et al
    Pepsinogen II in gastritis and Helicobacter pylori infection.
    Helicobacter. 2022 Jan 8:e12872. doi: 10.1111/hel.12872.
    PubMed     Abstract available

  30. XU C, Wu Y, Xu S
    Association between Helicobacter pylori infection and growth outcomes in children: A meta-analysis.
    Helicobacter. 2022 Jan 8:e12861. doi: 10.1111/hel.12861.
    PubMed     Abstract available

  31. CIFUENTES SG, Prado MB, Fornasini M, Cohen H, et al
    Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy.
    Helicobacter. 2022 Jan 6:e12870. doi: 10.1111/hel.12870.
    PubMed     Abstract available

    December 2021
  32. WANG L, Yao H, Tong T, Lau K, et al
    Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies.
    Helicobacter. 2021 Dec 30:e12871. doi: 10.1111/hel.12871.
    PubMed     Abstract available

  33. HUANG JG, Lim SYS, Aw MM, Quak SH, et al
    Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high-migrant Singaporean cohort.
    Helicobacter. 2021 Dec 27:e12868. doi: 10.1111/hel.12868.
    PubMed     Abstract available

    November 2021
  34. SHI H, Li Y, Dong C, Si G, et al
    Helicobacter pylori infection and the progression of atherosclerosis: A systematic review and meta-analysis.
    Helicobacter. 2021 Nov 28:e12865. doi: 10.1111/hel.12865.
    PubMed     Abstract available

  35. FERREIRA EO, Lagace-Wiens P, Klein J
    Campylobacter concisus gastritis masquerading as Helicobacter pylori on gastric biopsy.
    Helicobacter. 2021 Nov 24:e12864. doi: 10.1111/hel.12864.
    PubMed     Abstract available

  36. MURATA M, Sugimoto M, Miyamoto S, Kawai T, et al
    Long-term improvement in constipation-related symptoms after Helicobacter pylori eradication therapy.
    Helicobacter. 2021 Nov 17:e12863. doi: 10.1111/hel.12863.
    PubMed     Abstract available

  37. ZAGARI RM, Romano M, Frazzoni L, Marasco G, et al
    Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD.
    Helicobacter. 2021 Nov 11:e12862. doi: 10.1111/hel.12862.
    PubMed     Abstract available

    October 2021
  38. YU J, Yang P, Qin X, Li C, et al
    Impact of smoking on the eradication of Helicobacter pylori.
    Helicobacter. 2021 Oct 27:e12860. doi: 10.1111/hel.12860.
    PubMed     Abstract available

  39. CHEN MJ, Chen CC, Huang YC, Tseng CC, et al
    The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial.
    Helicobacter. 2021 Oct 27:e12857. doi: 10.1111/hel.12857.
    PubMed     Abstract available

  40. YANG C, Liang L, Lv P, Liu L, et al
    Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial.
    Helicobacter. 2021 Oct 10:e12856. doi: 10.1111/hel.12856.
    PubMed     Abstract available

  41. BENEJAT L, Ducournau A, Domingues-Martins C, Lecoeur M, et al
    Adaptation of an in-house PCR for the detection of Helicobacter pylori and the mutations associated with macrolide resistance into ready-to-use PCR microwell strips.
    Helicobacter. 2021 Oct 10:e12855. doi: 10.1111/hel.12855.
    PubMed     Abstract available

  42. LAPIDOT Y, Reshef L, Cohen D, Muhsen K, et al
    Helicobacter pylori and the intestinal microbiome among healthy school-age children.
    Helicobacter. 2021 Oct 7:e12854. doi: 10.1111/hel.12854.
    PubMed     Abstract available

    September 2021
  43. VARMA M, Yoe J
    Importance of testing for Helicobacter pylori in patients with immune thrombocytopenia.
    Helicobacter. 2021 Sep 22:e12850. doi: 10.1111/hel.12850.

  44. LUCERO Y, Lagomarcino AJ, Torres JP, Roessler P, et al
    Effect of Helicobacter pylori eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy school-aged children: A randomized non-blinded trial.
    Helicobacter. 2021 Sep 15:e12853. doi: 10.1111/hel.12853.
    PubMed     Abstract available

  45. ZHAO H, Yan P, Zhang N, Feng L, et al
    The recurrence rate of Helicobacter pylori in recent 10 years: A systematic review and meta-analysis.
    Helicobacter. 2021 Sep 12:e12852. doi: 10.1111/hel.12852.
    PubMed     Abstract available

  46. CHEN HY, Hu Y, Xu XB, Zhou YA, et al
    Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2.
    Helicobacter. 2021 Sep 7:e12849. doi: 10.1111/hel.12849.
    PubMed     Abstract available

  47. SUZUKI S, Gotoda T, Takano C, Horii T, et al
    Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes.
    Helicobacter. 2021 Sep 6:e12851. doi: 10.1111/hel.12851.
    PubMed     Abstract available

    August 2021
  48. YUAN Z, Xiao S, Li S, Suo B, et al
    The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults.
    Helicobacter. 2021 Aug 26:e12848. doi: 10.1111/hel.12848.
    PubMed     Abstract available

  49. YAO X, Xiao S, Zhou L
    Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication.
    Helicobacter. 2021 Aug 20:e12846. doi: 10.1111/hel.12846.
    PubMed     Abstract available

  50. LEE JW, Kim N, Nam RH, Jang JY, et al
    Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance.
    Helicobacter. 2021 Aug 12:e12844. doi: 10.1111/hel.12844.
    PubMed     Abstract available

  51. HSU PI, Tsay FW, Kao JY, Peng NJ, et al
    Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection.
    Helicobacter. 2021 Aug 12:e12840. doi: 10.1111/hel.12840.
    PubMed     Abstract available

  52. GUO R, Wu S, Guan L, Xie Y, et al
    Dietary multivalent anti-Helicobacter pylori immunoglobulin Y significantly increase the H. pylori eradication and improve the clinical symptoms in patients.
    Helicobacter. 2021 Aug 11:e12843. doi: 10.1111/hel.12843.
    PubMed     Abstract available

    July 2021
  53. GONG L, El-Omar EM
    Application of molecular techniques in Helicobacter pylori detection: limitations and improvements.
    Helicobacter. 2021 Jul 31:e12841. doi: 10.1111/hel.12841.

  54. OUYANG Y, Zhang W, Huang Y, Wang Y, et al
    Effect of Helicobacter pylori eradication on hyperplastic gastric polyps: A systematic review and meta-analysis.
    Helicobacter. 2021 Jul 31:e12838. doi: 10.1111/hel.12838.
    PubMed     Abstract available

  55. LI N, Xu X, Yang H, Wang H, et al
    Activation of Aquaporin 5 by carcinogenic Helicobacter pylori infection promotes epithelial-mesenchymal transition via the MEK/ERK pathway.
    Helicobacter. 2021 Jul 30:e12842. doi: 10.1111/hel.12842.
    PubMed     Abstract available

  56. ZHAO J, Zou Y, Li K, Huang X, et al
    Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis.
    Helicobacter. 2021 Jul 28:e12839. doi: 10.1111/hel.12839.
    PubMed     Abstract available

  57. ZOU PY, Hu J, Zhao JT, Zhao Z, et al
    10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis.
    Helicobacter. 2021 Jul 28:e12833. doi: 10.1111/hel.12833.
    PubMed     Abstract available

  58. KOWADA A, Asaka M
    Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
    Helicobacter. 2021 Jul 18:e12837. doi: 10.1111/hel.12837.
    PubMed     Abstract available

  59. GUNATHILAKE M, Lee J, Choi IJ, Kim YI, et al
    Association between bacteria other than Helicobacter pylori and the risk of gastric cancer.
    Helicobacter. 2021 Jul 15:e12836. doi: 10.1111/hel.12836.
    PubMed     Abstract available

  60. OUYANG Y, Zhu Z, Huang L, Zeng C, et al
    Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 2020.
    Helicobacter. 2021 Jul 13:e12835. doi: 10.1111/hel.12835.
    PubMed     Abstract available

  61. GUNARATNE AW, Hamblin H, Clancy A, Magat AJMC, et al
    Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.
    Helicobacter. 2021 Jul 10:e12830. doi: 10.1111/hel.12830.
    PubMed     Abstract available

    cagA+ Helicobacter pylori infection and N-nitrosodimethylamine and cholangiocarcinoma.
    Helicobacter. 2021 Jul 8:e12834. doi: 10.1111/hel.12834.

  63. MA H, Zhao XH, Zhang LL, Wu LM, et al
    Application of WeChat platform in the management of patients infected with Helicobacter pylori.
    Helicobacter. 2021 Jul 7:e12832. doi: 10.1111/hel.12832.
    PubMed     Abstract available

  64. HE Y, Ning J, Li B, Guo H, et al
    IL-9 contributes to the host immune response against Helicobacter pylori and helps limit infection in a Mouse Model.
    Helicobacter. 2021 Jul 7:e12827. doi: 10.1111/hel.12827.
    PubMed     Abstract available

    June 2021
  65. TSAI CF, Chen MH, Wang YP, Liu PY, et al
    Increased risk of short-term depressive disorder after Helicobacter pylori eradication: A population-based nested cohort study.
    Helicobacter. 2021 Jun 11:e12824. doi: 10.1111/hel.12824.
    PubMed     Abstract available

  66. QIU E, Jin S, Xiao Z, Chen Q, et al
    CRISPR-based detection of Helicobacter pylori in stool samples.
    Helicobacter. 2021 Jun 11:e12828. doi: 10.1111/hel.12828.
    PubMed     Abstract available

  67. KOTILEA K, Cadranel S, Salame A, Nguyen J, et al
    Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children.
    Helicobacter. 2021 Jun 7:e12825. doi: 10.1111/hel.12825.
    PubMed     Abstract available

    May 2021
  68. MONZANI A, Lionetti P, Rabbone I, Lionetti E, et al
    The best is the enemy of the good: Time for a biopsy-sparing approach for Helicobacter pylori diagnosis and treatment in children in the COVID-19 era?
    Helicobacter. 2021 May 28:e12826. doi: 10.1111/hel.12826.

  69. DANGTAKOT R, Intuyod K, Chamgramol Y, Pairojkul C, et al
    CagA(+) Helicobacter pylori infection and N-nitrosodimethylamine administration induce cholangiocarcinoma development in hamsters.
    Helicobacter. 2021 May 24:e12817. doi: 10.1111/hel.12817.
    PubMed     Abstract available

  70. LI C, Shi Y, Suo B, Tian X, et al
    PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis.
    Helicobacter. 2021 May 17:e12816. doi: 10.1111/hel.12816.
    PubMed     Abstract available

  71. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
    Acute gastric mucosal lesions caused by acute infection of non-Helicobacter pylori Helicobacter: a case report.
    Helicobacter. 2021 May 11:e12814. doi: 10.1111/hel.12814.
    PubMed     Abstract available

  72. ZHANG Z, Chen S, Fan M, Ruan G, et al
    Helicobacter pylori induces gastric cancer via down-regulating miR-375 to inhibit dendritic cell maturation.
    Helicobacter. 2021 May 3:e12813. doi: 10.1111/hel.12813.
    PubMed     Abstract available

    April 2021
  73. HERNANDEZ C, Toledo-Stuardo K, Garcia-Gonzalez P, Garrido-Tapia M, et al
    Heat-killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll-like receptor 4.
    Helicobacter. 2021 Apr 29:e12812. doi: 10.1111/hel.12812.
    PubMed     Abstract available

  74. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
    Prevalence, clinical features, and esophagogastroduodenoscopy (EGD) findings of non-Helicobacter pylori Helicobacter infection: A study of 50 cases at a single facility in Japan.
    Helicobacter. 2021 Apr 27:e12811. doi: 10.1111/hel.12811.
    PubMed     Abstract available

  75. WANG X, Shu X, Li Q, Li Y, et al
    Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high-risk area for gastric cancer in northwest China: An all-ages population-based cross-sectional study.
    Helicobacter. 2021 Apr 27:e12810. doi: 10.1111/hel.12810.
    PubMed     Abstract available

  76. ZHOU Y, Ye Z, Wang Y, Huang Z, et al
    Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children.
    Helicobacter. 2021 Apr 25:e12809. doi: 10.1111/hel.12809.
    PubMed     Abstract available

  77. LI SY, Li J, Dong XH, Teng GG, et al
    The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.
    Helicobacter. 2021 Apr 16:e12804. doi: 10.1111/hel.12804.
    PubMed     Abstract available

  78. XIE W, Zhao W, Zou Z, Kong L, et al
    Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice.
    Helicobacter. 2021 Apr 12:e12807. doi: 10.1111/hel.12807.
    PubMed     Abstract available

  79. DO AD, Chang CC, Su CH, Hsu YM, et al
    Lactobacillus rhamnosus JB3 inhibits Helicobacter pylori infection through multiple molecular actions.
    Helicobacter. 2021 Apr 11:e12806. doi: 10.1111/hel.12806.
    PubMed     Abstract available

  80. TURNER KO, Lindberg GM, Genta RM
    Gastric granulomas and Helicobacter pylori: An incidental relationship.
    Helicobacter. 2021 Apr 11:e12805. doi: 10.1111/hel.12805.
    PubMed     Abstract available

  81. YORGUC E, Gulerman HF, Kalkan IH, Guven B, et al
    Comparison of clinical outcomes and FOXP3, IL-17A responses in Helicobacter pylori infection in children versus adults.
    Helicobacter. 2021 Apr 5:e12795. doi: 10.1111/hel.12795.
    PubMed     Abstract available

  82. KUBOTA-AIZAWA S, Matsubara Y, Kanemoto H, Mimuro H, et al
    Transmission of Helicobacter pylori between a human and two dogs: A case report.
    Helicobacter. 2021 Apr 5:e12798. doi: 10.1111/hel.12798.
    PubMed     Abstract available

    March 2021
  83. LI Y, Li X, Tan Z
    An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis.
    Helicobacter. 2021 Mar 25:e12799. doi: 10.1111/hel.12799.
    PubMed     Abstract available

  84. CHIANG TH, Chen CC, Tseng PH, Liou JM, et al
    Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
    Helicobacter. 2021 Mar 19:e12801. doi: 10.1111/hel.12801.
    PubMed     Abstract available

  85. HEFFLEY JD, Zubarik R
    A standardized protocol improves testing rates for Helicobacter Pylori among inpatients with peptic ulcer disease.
    Helicobacter. 2021 Mar 15:e12800. doi: 10.1111/hel.12800.
    PubMed     Abstract available

  86. MARUBASHI K, Takakusagi S, Yokoyama Y, Kizawa K, et al
    Changes of (18) F-fluoro-2-deoxyglucose position-emission tomography findings by the eradication of Helicobacter pylori in the stomach.
    Helicobacter. 2021 Mar 8:e12797. doi: 10.1111/hel.12797.
    PubMed     Abstract available

  87. ZHAO JB, Yuan L, Yu XC, Shao QQ, et al
    Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis.
    Helicobacter. 2021 Mar 6:e12793. doi: 10.1111/hel.12793.
    PubMed     Abstract available

  88. JAIN U, Saxena K, Chauhan N
    Helicobacter pylori induced reactive oxygen Species: A new and developing platform for detection.
    Helicobacter. 2021 Mar 5:e12796. doi: 10.1111/hel.12796.
    PubMed     Abstract available

  89. TENG TZJ, Sudharsan M, Yau JWK, Tan W, et al
    Helicobacter pylori knowledge and perception among multi-ethnic Asians.
    Helicobacter. 2021 Mar 3:e12794. doi: 10.1111/hel.12794.
    PubMed     Abstract available

  90. KIM YJ, Chung WC, Kim DB
    Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
    Helicobacter. 2021 Mar 1:e12792. doi: 10.1111/hel.12792.
    PubMed     Abstract available

    February 2021
  91. HUANG Y, Ding Y, Xu H, Shen C, et al
    Effects of sodium butyrate supplementation on inflammation, gut microbiota, and short-chain fatty acids in Helicobacter pylori-infected mice.
    Helicobacter. 2021 Feb 20:e12785. doi: 10.1111/hel.12785.
    PubMed     Abstract available

  92. XIE M, Li Q, Zhang B, Zhang Q, et al
    Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients.
    Helicobacter. 2021 Feb 18:e12791. doi: 10.1111/hel.12791.
    PubMed     Abstract available

  93. GANTUYA B, El Serag HB, Saruuljavkhlan B, Azzaya D, et al
    Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis.
    Helicobacter. 2021 Feb 17:e12790. doi: 10.1111/hel.12790.
    PubMed     Abstract available

  94. LEE BE, Kim JS, Kim BW, Kim JH, et al
    Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years.
    Helicobacter. 2021 Feb 17:e12780. doi: 10.1111/hel.12780.
    PubMed     Abstract available

  95. WU ZF, Zou K, Xiang CJ, Jin ZJ, et al
    Helicobacter pylori infection is associated with the co-occurrence of bacteria in the oral cavity and the gastric mucosa.
    Helicobacter. 2021 Feb 17:e12786. doi: 10.1111/hel.12786.
    PubMed     Abstract available

  96. YANG KY, Kao CY, Su MS, Wang S, et al
    Glycosyltransferase Jhp0106 (PseE) contributes to flagellin maturation in Helicobacter pylori.
    Helicobacter. 2021 Feb 15:e12787. doi: 10.1111/hel.12787.
    PubMed     Abstract available

  97. LACOUT C, Savey L, Bourguiba R, Giurgea I, et al
    "Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france".
    Helicobacter. 2021 Feb 15:e12789. doi: 10.1111/hel.12789.
    PubMed     Abstract available

  98. ETO H, Suzuki S, Kusano C, Ikehara H, et al
    Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
    Helicobacter. 2021 Feb 12:e12788. doi: 10.1111/hel.12788.
    PubMed     Abstract available

  99. HU Y, Ouyang Y, Zhu Y, Lu NH, et al
    Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Helicobacter. 2021 Feb 3:e12784. doi: 10.1111/hel.12784.
    PubMed     Abstract available

    January 2021
  100. PARK Y, Kim TJ, Lee H, Yoo H, et al
    Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study.
    Helicobacter. 2021 Jan 28:e12783. doi: 10.1111/hel.12783.
    PubMed     Abstract available

  101. DOMANOVICH-ASOR T, Craddock HA, Motro Y, Khalfin B, et al
    Unraveling antimicrobial resistance in Helicobacter pylori: Global resistome meets global phylogeny.
    Helicobacter. 2021 Jan 25:e12782. doi: 10.1111/hel.12782.
    PubMed     Abstract available

  102. SONG X, Cai C, Jin Q, Chen X, et al
    The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis.
    Helicobacter. 2021 Jan 19:e12781. doi: 10.1111/hel.12781.
    PubMed     Abstract available

  103. WEN Y, Huang H, Tang T, Yang H, et al
    AI-2 represses CagA expression and bacterial adhesion, attenuating the Helicobacter pylori-induced inflammatory response of gastric epithelial cells.
    Helicobacter. 2021 Jan 5:e12778. doi: 10.1111/hel.12778.
    PubMed     Abstract available

  104. MUNOZ AB, Trespalacios-Rangel AA, Vale FF
    An American lineage of Helicobacter pylori prophages found in Colombia.
    Helicobacter. 2021 Jan 5:e12779. doi: 10.1111/hel.12779.
    PubMed     Abstract available

  105. JUNG K, Kim DH, Seo HI, Gong EJ, et al
    Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis.
    Helicobacter. 2021 Jan 5:e12774. doi: 10.1111/hel.12774.
    PubMed     Abstract available

    December 2020
  106. XUE Q, Li X, Li Y, Xu J, et al
    Dialogue between gastrointestinal tract and skin: New insights into the Helicobacter pylori and atopic dermatitis.
    Helicobacter. 2020 Dec 23:e12771. doi: 10.1111/hel.12771.
    PubMed     Abstract available

  107. QARIA MA, Qumar S, Sepe LP, Ahmed N, et al
    Cholesterol glucosylation-based survival strategy in Helicobacter pylori.
    Helicobacter. 2020 Dec 23:e12777. doi: 10.1111/hel.12777.
    PubMed     Abstract available

  108. KAKIUCHI T, Matsuo M, Endo H, Sakata Y, et al
    Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study.
    Helicobacter. 2020 Dec 23:e12776. doi: 10.1111/hel.12776.
    PubMed     Abstract available

  109. JUKIC I, Vukovic J, Rusic D, Bozic J, et al
    Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study.
    Helicobacter. 2020 Dec 23:e12775. doi: 10.1111/hel.12775.
    PubMed     Abstract available

  110. BANGA NDZOUBOUKOU JL, Lei Q, Ullah N, Zhang Y, et al
    Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori.
    Helicobacter. 2020 Dec 1:e12758. doi: 10.1111/hel.12758.
    PubMed     Abstract available

    November 2020
  111. CEN Q, Gao T, Ren Y, Lu X, et al
    Immune evaluation of a Saccharomyces cerevisiae-based oral vaccine against Helicobacter pylori in mice.
    Helicobacter. 2020 Nov 20:e12772. doi: 10.1111/hel.12772.
    PubMed     Abstract available

  112. GRAHAM DY, Megraud F
    Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy.
    Helicobacter. 2020 Nov 18:e12773. doi: 10.1111/hel.12773.

  113. SINGH H, Chung H, Awan I, Mone A, et al
    Designing strategies for eradication of Helicobacter pylori based on prevalence patterns of infection and antibiotic resistance in a low-income, medically underserved community in the United States.
    Helicobacter. 2020 Nov 9:e12769. doi: 10.1111/hel.12769.
    PubMed     Abstract available

    October 2020
  114. PIH GY, Choi KD, Gong EJ, Na HK, et al
    Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
    Helicobacter. 2020 Oct 28:e12759. doi: 10.1111/hel.12759.
    PubMed     Abstract available

  115. MEGRAUD F, Alix C, Charron P, Benejat L, et al
    Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years.
    Helicobacter. 2020 Oct 22:e12767. doi: 10.1111/hel.12767.
    PubMed     Abstract available

  116. KE H, Li J, Lu B, Yang C, et al
    The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.
    Helicobacter. 2020 Oct 21:e12768. doi: 10.1111/hel.12768.
    PubMed     Abstract available

  117. QUMAR S, Nguyen TH, Nahar S, Sarker N, et al
    A comparative whole genome analysis of Helicobacter pylori from a human dense South Asian setting.
    Helicobacter. 2020 Oct 18:e12766. doi: 10.1111/hel.12766.
    PubMed     Abstract available

  118. MIYATA E, Kudo T, Ikuse T, Tokita K, et al
    Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single-center study over 12 years.
    Helicobacter. 2020 Oct 18:e12764. doi: 10.1111/hel.12764.
    PubMed     Abstract available

  119. HOFREUTER D, Behrendt J, Franz A, Meyer J, et al
    Antimicrobial resistance of Helicobacter pylori in an eastern German region.
    Helicobacter. 2020 Oct 17:e12765. doi: 10.1111/hel.12765.
    PubMed     Abstract available

  120. SONG Z, Zhou L, Xue Y, Suo B, et al
    A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
    Helicobacter. 2020 Oct 11:e12762. doi: 10.1111/hel.12762.
    PubMed     Abstract available

  121. WANG B, Yu M, Zhang R, Chen S, et al
    A meta-analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease.
    Helicobacter. 2020 Oct 7:e12761. doi: 10.1111/hel.12761.
    PubMed     Abstract available

  122. ALVAREZ CS, Florio AA, Butt J, Rivera-Andrade A, et al
    Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala.
    Helicobacter. 2020 Oct 2:e12756. doi: 10.1111/hel.12756.
    PubMed     Abstract available

  123. HUANG JW, Xie C, Niu Z, He LJ, et al
    The relation between Helicobacter pylori immunoglobulin G seropositivity and leukocyte telomere length in US adults from NHANES 1999-2000.
    Helicobacter. 2020 Oct 1:e12760. doi: 10.1111/hel.12760.
    PubMed     Abstract available

    September 2020
  124. ARSLAN M, Balamtekin N, Gunal A
    Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children.
    Helicobacter. 2020 Sep 17:e12757. doi: 10.1111/hel.12757.
    PubMed     Abstract available

  125. ZHOU JJ, Shi X, Zheng SP, Tang D, et al
    Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China.
    Helicobacter. 2020 Sep 11:e12755. doi: 10.1111/hel.12755.
    PubMed     Abstract available

  126. SUAREZ-JARAMILLO A, Baldeon ME, Prado B, Fornasini M, et al
    Duodenal microbiome in patients with or without Helicobacter pylori infection.
    Helicobacter. 2020 Sep 8:e12753. doi: 10.1111/hel.12753.
    PubMed     Abstract available

  127. TAO ZH, Han JX, Fang JY
    Helicobacter pylori infection and eradication: Exploring their impacts on the gastrointestinal microbiota.
    Helicobacter. 2020 Sep 2:e12754. doi: 10.1111/hel.12754.
    PubMed     Abstract available

  128. GODBOLE G, Megraud F, Bessede E
    Review: Diagnosis of Helicobacter pylori infection.
    Helicobacter. 2020;25 Suppl 1:e12735.
    PubMed     Abstract available

  129. SEO JH, Bortolin K, Jones NL
    Review: Helicobacter pylori infection in children.
    Helicobacter. 2020;25 Suppl 1:e12742.
    PubMed     Abstract available

  130. DENIC M, Touati E, De Reuse H
    Review: Pathogenesis of Helicobacter pylori infection.
    Helicobacter. 2020;25 Suppl 1:e12736.
    PubMed     Abstract available

  131. O'CONNOR A, Furuta T, Gisbert JP, O'Morain C, et al
    Review - Treatment of Helicobacter pylori infection 2020.
    Helicobacter. 2020;25 Suppl 1:e12743.
    PubMed     Abstract available

  132. SCHULZ C, Kupcinskas J
    Review - Helicobacter pylori and non-malignant upper gastro-intestinal diseases.
    Helicobacter. 2020;25 Suppl 1:e12738.
    PubMed     Abstract available

  133. MEZMALE L, Coelho LG, Bordin D, Leja M, et al
    Review: Epidemiology of Helicobacter pylori.
    Helicobacter. 2020;25 Suppl 1:e12734.
    PubMed     Abstract available

  134. PELLICANO R, Ianiro G, Fagoonee S, Settanni CR, et al
    Review: Extragastric diseases and Helicobacter pylori.
    Helicobacter. 2020;25 Suppl 1:e12741.
    PubMed     Abstract available

    August 2020
  135. YUSIBOVA M, Hasman H, Clausen PTLC, Imkamp F, et al
    CRHP Finder, a webtool for the detection of clarithromycin resistance in Helicobacter pylori from whole-genome sequencing data.
    Helicobacter. 2020 Aug 26:e12752. doi: 10.1111/hel.12752.
    PubMed     Abstract available

  136. ESLICK GD, Tilden D, Arora N, Torres M, et al
    Clinical and economic impact of "triple therapy" for Helicobacter pylori eradication on peptic ulcer disease in Australia.
    Helicobacter. 2020 Aug 20:e12751. doi: 10.1111/hel.12751.
    PubMed     Abstract available

  137. SALEHI N, Attaran B, Zare-Mirakabad F, Ghadiri B, et al
    The outward shift of clarithromycin binding to the ribosome in mutant Helicobacter pylori strains.
    Helicobacter. 2020 Aug 14:e12731. doi: 10.1111/hel.12731.
    PubMed     Abstract available

  138. NAKAMURA M, Overby A, Michimae H, Matsui H, et al
    PCR analysis and specific immunohistochemistry revealing a high prevalence of non-Helicobacter pylori Helicobacters in Helicobacter pylori-negative gastric disease patients in Japan: High susceptibility to an Hp eradication regimen.
    Helicobacter. 2020 Aug 13:e12700. doi: 10.1111/hel.12700.
    PubMed     Abstract available

  139. GUDRA D, Pupola D, Skenders G, Leja M, et al
    Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 years after a single eradication event.
    Helicobacter. 2020 Aug 9:e12748. doi: 10.1111/hel.12748.
    PubMed     Abstract available

  140. ZHANG Y, Dong Q, Tian L, Zhang S, et al
    Risk factors for recurrence of Helicobacter pylori infection after successful eradication in Chinese children: A prospective, nested case-control study.
    Helicobacter. 2020 Aug 7:e12749. doi: 10.1111/hel.12749.
    PubMed     Abstract available

  141. GONG EJ, Ahn JY, Jung DK, Lee SM, et al
    Isolation of Helicobacter pylori using leftover tissue in the rapid urease test kit.
    Helicobacter. 2020 Aug 3:e12733. doi: 10.1111/hel.12733.
    PubMed     Abstract available

    July 2020
  142. KAWAHARA Y, Hirashita Y, Tamura C, Kudo Y, et al
    Helicobacter pylori infection modulates endogenous hydrogen sulfide production in gastric cancer AGS cells.
    Helicobacter. 2020 Jul 26:e12732. doi: 10.1111/hel.12732.
    PubMed     Abstract available

  143. HWONG-RUEY LEOW A, Chang JV, Goh KL
    Searching for an optimal therapy for H pylori eradication: High-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days.
    Helicobacter. 2020 Jul 26:e12723. doi: 10.1111/hel.12723.
    PubMed     Abstract available

  144. SHOLEH M, Maleki F, Krutova M, Bavari S, et al
    The increasing antimicrobial resistance of Helicobacter pylori in Iran: A systematic review and meta-analysis.
    Helicobacter. 2020 Jul 23:e12730. doi: 10.1111/hel.12730.
    PubMed     Abstract available

  145. KHIDDI F, Abdellahi MVM, Horma MA, Billoet A, et al
    Characteristics of Helicobacter pylori strains isolated from Mauritanian patients.
    Helicobacter. 2020 Jul 19:e12726. doi: 10.1111/hel.12726.
    PubMed     Abstract available

  146. PUNDAK OY, Topf Olivestone C, Hofi L, Kori M, et al
    Lack of association between Helicobacter pylori infection and childhood overweight/obesity.
    Helicobacter. 2020 Jul 19:e12728. doi: 10.1111/hel.12728.
    PubMed     Abstract available

  147. LI M, Sun Y, Yang J, de Martel C, et al
    Time trends and other sources of variation in Helicobacter pylori infection in mainland China: A systematic review and meta-analysis.
    Helicobacter. 2020 Jul 19:e12729. doi: 10.1111/hel.12729.
    PubMed     Abstract available

  148. WINDHAM IH, Merrell DS
    Analysis of fitness costs associated with metronidazole and amoxicillin resistance in Helicobacter pylori.
    Helicobacter. 2020 Jul 16:e12724. doi: 10.1111/hel.12724.
    PubMed     Abstract available

  149. PAL S, Sarker N, Qaria M, Tandon K, et al
    Design of an inhibitor of Helicobacter pylori cholesteryl-alpha-glucoside transferase critical for bacterial colonization.
    Helicobacter. 2020 Jul 15:e12720. doi: 10.1111/hel.12720.
    PubMed     Abstract available

  150. HEYDARI S, Siavoshi F, Jazayeri MH, Sarrafnejad A, et al
    Helicobacter pylori release from yeast as a vesicle-encased or free bacterium.
    Helicobacter. 2020 Jul 14:e12725. doi: 10.1111/hel.12725.
    PubMed     Abstract available

  151. NYSSEN OP, Perez-Aisa A, Rodrigo L, Castro M, et al
    Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
    Helicobacter. 2020 Jul 13:e12722. doi: 10.1111/hel.12722.
    PubMed     Abstract available

    June 2020
  152. HIRATA Y, Yamada A, Niikura R, Shichijo S, et al
    Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
    Helicobacter. 2020 Jun 29:e12719. doi: 10.1111/hel.12719.
    PubMed     Abstract available

  153. DEMIR AM, Berberoglu Ates B, Hizal G, Yaman A, et al
    Autoimmune atrophic gastritis: The role of Helicobacter pylori infection in children.
    Helicobacter. 2020 Jun 26:e12716. doi: 10.1111/hel.12716.
    PubMed     Abstract available

  154. GOKISIK MT, Uyar S
    The role of Helicobacter pylori in vitamin-B12 deficiency due to metformin use.
    Helicobacter. 2020 Jun 19:e12718. doi: 10.1111/hel.12718.
    PubMed     Abstract available

  155. CAI Y, Wang C, Chen Z, Xu Z, et al
    Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in Helicobacter pylori by enhancing drug efflux.
    Helicobacter. 2020 Jun 16:e12715. doi: 10.1111/hel.12715.
    PubMed     Abstract available

  156. ZOU Y, Qian X, Liu X, Song Y, et al
    The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis.
    Helicobacter. 2020 Jun 12:e12714. doi: 10.1111/hel.12714.
    PubMed     Abstract available

  157. YE Q, Shao X, Shen R, Chen D, et al
    Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis.
    Helicobacter. 2020 Jun 9:e12713. doi: 10.1111/hel.12713.
    PubMed     Abstract available

    May 2020
  158. WU Y, Su T, Zhou X, Lu N, et al
    Awareness and attitudes regarding Helicobacter pylori infection in Chinese physicians and public population: A national cross-sectional survey.
    Helicobacter. 2020 May 31:e12705. doi: 10.1111/hel.12705.
    PubMed     Abstract available

  159. JAIN U, Gupta S, Soni S, Khurana MP, et al
    Triple-nanostructuring-based noninvasive electro-immune sensing of CagA toxin for Helicobacter pylori detection.
    Helicobacter. 2020 May 29:e12706. doi: 10.1111/hel.12706.
    PubMed     Abstract available

  160. SEO KI, Heo JJ, Kim SE, Park SJ, et al
    Sex differences between Helicobacter pylori infection and cholesterol levels in an adult health checkup program.
    Helicobacter. 2020 May 26:e12704. doi: 10.1111/hel.12704.
    PubMed     Abstract available

  161. TANG X, Shen Y, Hu R, Yang T, et al
    Re-assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori.
    Helicobacter. 2020 May 26:e12703. doi: 10.1111/hel.12703.
    PubMed     Abstract available

  162. LUO L, Huang Y, Liang X, Ji Y, et al
    Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies.
    Helicobacter. 2020 May 19:e12699. doi: 10.1111/hel.12699.
    PubMed     Abstract available

  163. JEHANNE Q, Benejat L, Megraud F, Bessede E, et al
    Evaluation of the Allplex H pylori and ClariR PCR Assay for Helicobacter pylori detection on gastric biopsies.
    Helicobacter. 2020 May 19:e12702. doi: 10.1111/hel.12702.
    PubMed     Abstract available

  164. ZHANG J, Chen Y, Chen W, Xu H, et al
    Persistent infection of Helicobacter pylori affects weight loss in obese population compared with persistent negative: A case-control study based on healthy Chinese.
    Helicobacter. 2020 May 15:e12697. doi: 10.1111/hel.12697.
    PubMed     Abstract available

  165. MIFTAHUSSURUR M, Waskito LA, El-Serag HB, Ajami NJ, et al
    Gastric microbiota and Helicobacter pylori in Indonesian population.
    Helicobacter. 2020 May 12:e12695. doi: 10.1111/hel.12695.
    PubMed     Abstract available

  166. HORIE R, Handa O, Ando T, Ose T, et al
    Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
    Helicobacter. 2020 May 5:e12698. doi: 10.1111/hel.12698.
    PubMed     Abstract available

    April 2020
  167. KAJI E, Yoden A, Otani M, Okuhira T, et al
    Helicobacter pylori test-and-treat strategy for second-year junior high school students aimed at the prevention of gastric cancer in Takatsuki City.
    Helicobacter. 2020 Apr 30:e12696. doi: 10.1111/hel.12696.
    PubMed     Abstract available

  168. GAO CP, Zhang D, Zhang T, Wang JX, et al
    PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis.
    Helicobacter. 2020 Apr 20:e12692. doi: 10.1111/hel.12692.
    PubMed     Abstract available

  169. BERESNIAK A, Malfertheiner P, Franceschi F, Liebaert F, et al
    Helicobacter pylori "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative.
    Helicobacter. 2020 Apr 13:e12693. doi: 10.1111/hel.12693.
    PubMed     Abstract available

  170. BAYRAK NA, Tutar E, Volkan B, Sahin Akkelle B, et al
    Helicobacter pylori infection in children with celiac disease: Multi-center, cross-sectional study.
    Helicobacter. 2020 Apr 1:e12691. doi: 10.1111/hel.12691.
    PubMed     Abstract available

    March 2020
  171. KAKIUCHI T, Mizoe A, Yamamoto K, Imamura I, et al
    Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial.
    Helicobacter. 2020 Mar 24:e12690. doi: 10.1111/hel.12690.
    PubMed     Abstract available

  172. DOORAKKERS E, Lagergren J, Santoni G, Engstrand L, et al
    Helicobacter pylori eradication treatment and the risk of Barrett's esophagus and esophageal adenocarcinoma.
    Helicobacter. 2020 Mar 16:e12688. doi: 10.1111/hel.12688.
    PubMed     Abstract available

  173. NYSSEN OP, Perez-Aisa A, Tepes B, Rodrigo-Saez L, et al
    Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).
    Helicobacter. 2020 Mar 16:e12686. doi: 10.1111/hel.12686.
    PubMed     Abstract available

  174. ALBERTS CJ, Jeske R, de Martel C, den Hollander WJ, et al
    Helicobacter pylori seroprevalence in six different ethnic groups living in Amsterdam: The HELIUS study.
    Helicobacter. 2020 Mar 9:e12687. doi: 10.1111/hel.12687.
    PubMed     Abstract available

  175. YOON K, Kim N, Lee JW, Yoon H, et al
    Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
    Helicobacter. 2020 Mar 6:e12685. doi: 10.1111/hel.12685.
    PubMed     Abstract available

    February 2020
  176. ARSHAD U, Sarkar S, Alipour Talesh G, Sutton P, et al
    A lack of role for antibodies in regulating Helicobacter pylori colonization and associated gastritis.
    Helicobacter. 2020 Feb 23:e12681. doi: 10.1111/hel.12681.
    PubMed     Abstract available

  177. LUO M, Hao Y, Tang M, Shi M, et al
    Application of a social media platform as a patient reminder in the treatment of Helicobacter pylori.
    Helicobacter. 2020 Feb 23:e12682. doi: 10.1111/hel.12682.
    PubMed     Abstract available

  178. HAMIDI S, Badmasti F, Sadeghpour Heravi F, Safapoor MH, et al
    Antibiotic resistance and clonal relatedness of Helicobacter pylori strains isolated from stomach biopsy specimens in northeast of Iran.
    Helicobacter. 2020 Feb 19:e12684. doi: 10.1111/hel.12684.
    PubMed     Abstract available

  179. KIM JY, Lee SY, Kim JH, Sung IK, et al
    Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication.
    Helicobacter. 2020 Feb 19:e12683. doi: 10.1111/hel.12683.
    PubMed     Abstract available

  180. SELIGOVA B, Lukac L, Babelova M, Vavrova S, et al
    Diagnostic reliability of nested PCR depends on the primer design and threshold abundance of Helicobacter pylori in biopsy, stool, and saliva samples.
    Helicobacter. 2020 Feb 14:e12680. doi: 10.1111/hel.12680.
    PubMed     Abstract available

    January 2020
  181. ZHOU Y, Ye Z, Wang Y, Zhang Y, et al
    Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
    Helicobacter. 2020 Jan 20:e12679. doi: 10.1111/hel.12679.
    PubMed     Abstract available

    December 2019
  182. KADKHODAEI S, Siavoshi F, Akbari Noghabi K
    Mucoid and coccoid Helicobacter pylori with fast growth and antibiotic resistance.
    Helicobacter. 2019 Dec 26:e12678. doi: 10.1111/hel.12678.
    PubMed     Abstract available

  183. SHAMSDIN SA, Alborzi A, Ghaderi A, Lankrani KB, et al
    Significance of TC9 and TH9 in Helicobacter pylori-induced gastritis.
    Helicobacter. 2019 Dec 5:e12672. doi: 10.1111/hel.12672.
    PubMed     Abstract available

    November 2019
  184. MIAO R, Wan C, Wang Z
    The relationship of gastric microbiota and Helicobacter pylori infection in pediatrics population.
    Helicobacter. 2019 Nov 24:e12676. doi: 10.1111/hel.12676.
    PubMed     Abstract available

  185. BUTT J, Blot WJ, Shrubsole MJ, Varga MG, et al
    Performance of multiplex serology in discriminating active vs past Helicobacter pylori infection in a primarily African American population in the southeastern United States.
    Helicobacter. 2019 Nov 20:e12671. doi: 10.1111/hel.12671.
    PubMed     Abstract available

  186. MUHSEN K, Na'amnih W, Adler A, Carmeli Y, et al
    Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study.
    Helicobacter. 2019 Nov 13:e12668. doi: 10.1111/hel.12668.
    PubMed     Abstract available

  187. ROCHA GA, de Melo FF, Cabral MMDA, de Brito BB, et al
    Interleukin-27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori-associated gastroduodenal diseases.
    Helicobacter. 2019 Nov 8:e12667. doi: 10.1111/hel.12667.
    PubMed     Abstract available

  188. KOCSMAR E, Kocsmar I, Buzas GM, Szirtes I, et al
    Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept.
    Helicobacter. 2019 Nov 8:e12670. doi: 10.1111/hel.12670.
    PubMed     Abstract available

  189. PAPAEFTHYMIOU A, Liatsos C, Georgopoulos SD, Apostolopoulos P, et al
    Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.
    Helicobacter. 2019 Nov 6:e12666. doi: 10.1111/hel.12666.
    PubMed     Abstract available

  190. KISHIKAWA H, Ojiro K, Nakamura K, Katayama T, et al
    Previous Helicobacter pylori infection-induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication.
    Helicobacter. 2019 Nov 3:e12669. doi: 10.1111/hel.12669.
    PubMed     Abstract available

    October 2019
  191. PONZETTO A, Figura N
    Prevalence of ischemic stroke and Helicobacter pylori infection.
    Helicobacter. 2019 Oct 27:e12664. doi: 10.1111/hel.12664.

  192. GUO Y, Zhang T, Shi Y, Zhang J, et al
    Helicobacter pylori inhibits GKN1 expression via the CagA/p-ERK/AUF1 pathway.
    Helicobacter. 2019 Oct 27:e12665. doi: 10.1111/hel.12665.
    PubMed     Abstract available

  193. YU Y, Yao X, Liang J, Lu C, et al
    Is Helicobacter pylori associated with Behcet's syndrome? A meta-analysis.
    Helicobacter. 2019 Oct 16:e12663. doi: 10.1111/hel.12663.
    PubMed     Abstract available

  194. SONG C, Xie C, Zhu Y, Liu W, et al
    Management of Helicobacter pylori infection by clinicians: A nationwide survey in a developing country.
    Helicobacter. 2019 Oct 1:e12656. doi: 10.1111/hel.12656.
    PubMed     Abstract available

    September 2019
  195. DE SENA-REIS JS, Bezerra DD, Figueiredo CA, Barreto ML, et al
    Relationship between African Biogeographical Ancestry and Helicobacter pylori infection in children of a large Latin American urban center.
    Helicobacter. 2019 Sep 30:e12662. doi: 10.1111/hel.12662.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.